Bevacizumab-awwb is named as a drug or biological intervention in 2 clinical trials in our UK, USA and China trial registers, 1 of which is recruiting. The lead sponsor is Amgen. Registered phases: Phase 1 and Phase 3. Conditions studied include Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation; Metastatic Colorectal Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (ClinicalTrials.gov ↗) Metastatic Colorectal Cancer |
Phase 3 | Recruiting |
| NCT04185883 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Solid Tumors | 1 |
| Kirsten Rat Sarcoma (KRAS) pG12C Mutation | 1 |
| Metastatic Colorectal Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Amgen | 2 |
| Register | Bevacizumab-awwb trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bevacizumab-awwb works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bevacizumab-awwb (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.